Introduction
Antibiotic abuse and misuse are recognized as important determinant factors for the development of antibiotic resistance. 1, 2 Although frequent calls to stop the excessive use of antibiotics have been made, 1 both consumption and resistance are tending to escalate in some countries. 2 To prevent further spread of resistance and to develop effective strategies to foster appropriate antibiotic consumption in all European countries, international cooperation is necessary starting with setting up reliable surveillance systems of both antibiotic resistance and consumption. 1 In 2001, the European Commission (Directorate-General Sanco, Health Monitoring Program) established the European Surveillance of Antimicrobial Consumption (ESAC) project. The aim of the project was to collect data on antibiotic consumption in Europe from publicly available sources and to assess the time trends in human exposure to antibiotics. 2, 3 Spain shows increased rates of antibiotic resistance in several community pathogens in comparison with other European countries. 4, 5 A number of authors and international Health Institutions have identified uncontrolled self-medication and over-the-counter (OTC) consumption of antibiotics as a key health problem for the effective control of antibiotic resistance. 6 Although community pharmacies in most European Union countries are not legally allowed to dispense antibiotics without a prescription, this is a common practice at least in some of the European countries, and one that can lead to a high OTC consumption.
In Spain ( population~45 million people), important differences in the outpatient consumption of antibiotics have been observed depending on the measurement system used. In the study by Cars et al., 7 based on wholesaler sales data provided by International Medical Statistics (IMS) Health, total outpatient antibiotic consumption in Spain was among the highest in Europe, second only to France; however, consumption figures were much lower according to official reimbursement data by the social security system. 2 Nonetheless, these differences have not been studied in detail.
On the other hand, several studies have suggested that Spain may present high rates of self-antibiotic consumption and OTC consumption in comparison with other European countries. 6, 8 However, despite their evident public health interest, rates of OTC antibiotic consumption are not well understood.
In this study, we analysed the community consumption of antibacterials for systemic use in Spain according to sales data (SD) and reimbursement data (RD). database of retail pharmacy sales of all medicines acquired with National Health System prescriptions, covering nearly 100% of the Spanish population. In addition, wholesaler SD for 2002, 2004 and 2005 were obtained from IMS Health at the level of active substances, expressed in kg or IU, which allowed assignment of the ATC codes and conversion into DDD. The IMS Health information is sourced from a mixed sample of wholesalers and pharmacies which represents 96.5% of sales to retail pharmacies in Spain, this being projected to a national total.
Materials and methods
In-depth analysis of differences between both data sources was further performed. (Table 1) . This increase was almost exclusively due to amoxicillin/ clavulanic acid use with an increase of 2.34 (RD) and 2.46 (SD) DID. The consumption of the majority of the other antibiotics Considerable differences between RD and SD were found for the 20 most used antibiotics, representing over 95% of Spanish outpatient antibiotic use (Table 1 ). These differences were most marked for amoxicillin (48.2% in 2005), cefpodoxime (49.2%), clindamycin (51.1%), cefaclor (51.9%), fosfomycin (58.6%), erythromycin (72%) and spiramycin (89.6%). However, differences in the use of amoxicillin and amoxicillin/clavulanic acid (3.65 and 1.93 DID, respectively, in 2005) accounted together for 57.9% of the overall difference between RD and SD in 2005. Conversely, the smallest differences were found for fluoroquinolones: moxifloxacin (15.4% in 2005), levofloxacin (14.8%) and ciprofloxacin (13.1%).
Results and discussion
During the study period, the proportion of difference between RD and SD remained constant for most antibiotic classes. However, an important increase (.10%) was detected in cefuroxime, 12. (Table 1) . However, the proportion of annual difference RD 2 SD has slightly decreased for amoxicillin/clavulanic acid during this period, which is probably related to the increasing share in the consumption of the higher strength formulations (data not shown).
Drug utilization reports can stem either from RD or SD. Both sources have their specific biases: RD exclude the OTC sales, but also the prescriptions made in private practice and within healthcare maintenance organizations for certain civil servants, while SD may include parallel export to other countries and veterinary use. In many European countries, all antibiotics are at least partially reimbursed. However, in some countries, as is the case of some northern European countries, several antibiotics are excluded from the reimbursement list either because they are considered as inappropriate or because their reimbursement is limited to certain diagnoses or population groups. Furthermore in countries with data collection systems based on RD as is the case of Spain, the delivery of antibiotics as OTC medicines may lead to an underestimation of the overall antibiotic consumption.
This was documented in Spain by in-depth analysis of differences between two parallel data sets based on both RD and SD. These may provide a good estimate of non-reimbursed ( principally OTC) sales, although disparity between SD and RD could also be explained in part by additional factors like private health insurance and pet veterinary prescriptions, both not included in RD, and parallel re-exports to other EU countries. Spain, as a country with lower medicine prices within the EU, is considered as a source country for parallel exports to countries with higher price levels. 10 Dentistry is mostly private in Spain and thus antibiotic prescriptions made by such professionals are largely outside RD, explaining for instance the great difference observed between RD and SD for spiramycin (89.6%), an antibiotic almost exclusively used in this medical field in Spain (combination of spiramycin plus metronidazole). However, OTC antibiotics do not represent the total rates of self-medication with antibiotics. A recent comparative European study observed a high prevalence of self-medication with antibiotics and storage in Spain suggesting that an important part of the self-medication may be due to the use of antibiotics from leftovers. 11 In this study, outpatient antibiotic consumption was relatively high in Spain, according to SD, with a substantial difference in RD 2 SD information that indirectly could be an indicator of OTC consumption, although prescriptions derived from private practice, civil servants or veterinary use may also have a contribution. The highest deviation between the two sources of information was observed for amoxicillin, fosfomycin and erythromycin, old and inexpensive antibiotics, which suggests that parallel exports may not have played a relevant role in the overall difference RD 2 SD. Old and inexpensive antibiotics such as amoxicillin, fosfomycin and erythromycin tend to be more frequently purchased OTC than new and expensive ones, such as the new fluoroquinolones.
According to ESAC published data based on RD, 2 in 2002 total antibiotic consumption in Spain was close to the average for European countries; however, if the SD for the same year reported in this study were considered, Spain would have been in the five highest antibiotic consumers among European countries, probably a much more realistic position.
Recently, Spain launched a mass media public campaign aimed at promoting a more rational use of antibiotics including the reduction of self-medication and OTC (http://www.antibioticos.msc.es/home.html). The two measurement systems analysed in this study would be useful to measure the campaign impact in general and the reduction in the OTC use in particular.
In summary, in this study we have shown that estimation of the total outpatient antibiotic consumption in Spain strongly varies according to the measurement system. Sales data suggest that~30% of the total antibiotic consumption was not registered by the reimbursement data of the National Health System. These differences were particularly significant for the most prescribed antibiotics amoxicillin/clavulanic acid, amoxicillin, clarithromycin and cefuroxime. OTC use of antibiotics in this country may account for an important proportion of these differences.
